Sgd Pharma Sustainability Profile
Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the design and manufacture of glass primary packaging solutions. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the pharmaceutical and biotechnology sectors. With a commitment to quality and innovation, Sgd Pharma offers a comprehensive range of products, including vials, ampoules, and syringes, all designed to meet stringent regulatory standards. Their unique approach combines advanced manufacturing techniques with a focus on sustainability, positioning them as a trusted partner for global pharmaceutical companies. Notably, Sgd Pharma has achieved significant milestones in product development and market expansion, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Sgd Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Rubber and Plastic Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sgd Pharma's score of 35 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sgd Pharma's reported carbon emissions
In 2023, SGD Pharma reported total carbon emissions of approximately 203,584,000 kg CO2e for Scope 1, 199,732,000 kg CO2e for Scope 2, and 10,000,000 kg CO2e for Scope 3. The company has set ambitious climate commitments, aiming for a 42% reduction in Scope 1 and 2 emissions by 2030 compared to 2022 levels, and a long-term goal of achieving carbon neutrality by 2050. Additionally, SGD Pharma plans to cut CO2 emissions from its plants in France, Germany, India, and China by 35% by 2030 and by 65% by 2040, using a 2020 baseline for both targets. These initiatives align with the 1.5°C climate threshold and reflect the company's commitment to sustainability within the containers and packaging sector. All emissions data is sourced directly from SGD Pharma, with no cascaded data from parent organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
How Carbon Intensive is Sgd Pharma's Industry?
How Carbon Intensive is Sgd Pharma's Location?
Sgd Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sgd Pharma has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Frequently Asked Questions
Common questions about Sgd Pharma's sustainability data and climate commitments